AR058249A2 - Una molecula aislada de polinucleotido que comprende una secuencia de adn que codifica una molecula infecciosa de arn que codifica un virus prrs norteamericano, celula transfectada y vacuna - Google Patents

Una molecula aislada de polinucleotido que comprende una secuencia de adn que codifica una molecula infecciosa de arn que codifica un virus prrs norteamericano, celula transfectada y vacuna

Info

Publication number
AR058249A2
AR058249A2 ARP070101362A AR058249A2 AR 058249 A2 AR058249 A2 AR 058249A2 AR P070101362 A ARP070101362 A AR P070101362A AR 058249 A2 AR058249 A2 AR 058249A2
Authority
AR
Argentina
Prior art keywords
molecula
nucleotide
dna sequence
prrs virus
vaccine
Prior art date
Application number
Other languages
English (en)
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of AR058249A2 publication Critical patent/AR058249A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/10011—Arteriviridae
    • C12N2770/10021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/10011—Arteriviridae
    • C12N2770/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/10011—Arteriviridae
    • C12N2770/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2770/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/10011—Arteriviridae
    • C12N2770/10061—Methods of inactivation or attenuation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/10011—Arteriviridae
    • C12N2770/10061—Methods of inactivation or attenuation
    • C12N2770/10062—Methods of inactivation or attenuation by genetic engineering

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pulmonology (AREA)
  • Pregnancy & Childbirth (AREA)

Abstract

Una molécula aislada de polinucléotido caracterizada porque comprende una secuencia de ADN que codifica una molécula infecciosa de ARN que codifica un virus PRRS norteamericano que está genéticamente modificado de modo tal que comprende uno o más epítopes antigénicos heterologos, donde la secuencia de ADN que codifica la molécula de ARN que codifica el virus PRRS norteamericano es SEQ ID. N°1 o es la secuencia que comienza con e incluye desde el nucleotido 1 hasta incluir el nucleotido 15416 de la SEQ ID. N°1; excepto que el nucleotido que corresponde al nucleotido 12622 de la SEQ ID. N° 1 es una guanina en un lugar de una adenina y el nucleotido que corresponde al nucleotido 1559 de la SEQ. ID. N° 1 es una timina en lugar de una citosina, excepto que comprende uno o más secuencias de nucleotidos adicionales que codifican epítopes antigénicos heterologos, donde cada epítope antigénico heterologo es capaz de inducir una respuesta inmunoportectora efectiva contra un patogeno particular en un mamífero o en un pájaro. Se describe también una célula huésped transfectada, y una vacuna.
ARP070101362 1998-12-22 2007-03-30 Una molecula aislada de polinucleotido que comprende una secuencia de adn que codifica una molecula infecciosa de arn que codifica un virus prrs norteamericano, celula transfectada y vacuna AR058249A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11334598P 1998-12-22 1998-12-22

Publications (1)

Publication Number Publication Date
AR058249A2 true AR058249A2 (es) 2008-01-30

Family

ID=22348908

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP990106325 AR025146A1 (es) 1998-12-22 1999-12-13 UNA MOLÉCULA AISLADA DE POLINUCLEoTIDO QUE COMPRENDE UNA SECUENCIA DE ADN QUE CODIFICA UN VIRUS PRRS NORTEAMERICANO, CÉLULA HUESPED, PLÁSMIDO, MÉTODO PARA GENERAR UN VIRUS PRRS NORTEAMERICANO Y VACUNA.
ARP070101362 AR058249A2 (es) 1998-12-22 2007-03-30 Una molecula aislada de polinucleotido que comprende una secuencia de adn que codifica una molecula infecciosa de arn que codifica un virus prrs norteamericano, celula transfectada y vacuna

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP990106325 AR025146A1 (es) 1998-12-22 1999-12-13 UNA MOLÉCULA AISLADA DE POLINUCLEoTIDO QUE COMPRENDE UNA SECUENCIA DE ADN QUE CODIFICA UN VIRUS PRRS NORTEAMERICANO, CÉLULA HUESPED, PLÁSMIDO, MÉTODO PARA GENERAR UN VIRUS PRRS NORTEAMERICANO Y VACUNA.

Country Status (17)

Country Link
US (2) US6500662B1 (es)
EP (2) EP1627919B1 (es)
JP (7) JP4113642B2 (es)
CN (1) CN1171996C (es)
AR (2) AR025146A1 (es)
AT (1) ATE309364T1 (es)
AU (1) AU769841B2 (es)
BR (1) BRPI9905902B8 (es)
CA (2) CA2290220C (es)
CY (2) CY1105680T1 (es)
DE (1) DE69928209T9 (es)
DK (2) DK1018557T5 (es)
ES (2) ES2459568T3 (es)
MX (1) MXPA03009354A (es)
NZ (2) NZ513289A (es)
PT (1) PT1627919E (es)
ZA (1) ZA997289B (es)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040224327A1 (en) * 1996-10-30 2004-11-11 Meulenberg Johanna Jacoba Maria Infectious clones of RNA viruses and vaccines and diagnostic assays derived thereof
EP0839912A1 (en) * 1996-10-30 1998-05-06 Instituut Voor Dierhouderij En Diergezondheid (Id-Dlo) Infectious clones of RNA viruses and vaccines and diagnostic assays derived thereof
US7618797B2 (en) * 1998-12-22 2009-11-17 Pfizer Inc Infectious cDNA clone of North American porcine reproductive and respiratory syndrome (PRRS) virus and uses thereof
US7691389B2 (en) * 1998-12-22 2010-04-06 Pfizer Inc Infectious cDNA clone of north american porcine reproductive and respiratory syndrome (PRRS) virus and uses thereof
CA2366072C (en) 1999-03-08 2007-07-10 Id-Lelystad, Instituut Voor Dierhouderij En Diergezondheid B.V. Prrsv vaccines
MXPA01010681A (es) 1999-04-22 2003-08-20 Us Agriculture Vacuna de sindrome respiratorio y reproductiva porcina a base de ja-142 aislado.
WO2002038753A1 (en) * 2000-11-09 2002-05-16 Junichi Watanabe Method of screening gene affecting pathological conditions or survival of animal infected with pathogen
US6841364B2 (en) * 2002-01-22 2005-01-11 Protatek International, Inc. Infectious cDNA clones of porcine reproductive and respiratory syndrome virus and expression vectors thereof
US7906311B2 (en) 2002-03-20 2011-03-15 Merial Limited Cotton rat lung cells for virus culture
US7371395B2 (en) * 2003-07-24 2008-05-13 Merial Limited Vaccine formulations
RU2007101725A (ru) 2004-06-18 2008-07-27 Риджентс Оф Дзе Юниверсити Оф Миннесота (Us) Идентификация инфицированных вирусом и вакцинированных вирусом организмов
KR100872840B1 (ko) 2004-07-09 2008-12-22 (주)씨아이디 돼지생식기호흡기증후군 바이러스에 대한 전체-길이의감염성이 있는 cDNA 클론 및 이의 용도
US7632636B2 (en) * 2004-09-21 2009-12-15 Boehringer Ingelheim Vetmedica, Inc. Porcine reproductive and respiratory syndrome isolates and methods of use
US7879337B2 (en) * 2004-11-11 2011-02-01 Pfizer Inc. Mutant porcine reproductive and respiratory syndrome virus
KR20070096019A (ko) 2005-01-13 2007-10-01 베링거잉겔하임베트메디카게엠베하 향상된 ｐｒｒｓ 백신
RU2381035C2 (ru) * 2005-02-25 2010-02-10 Пфайзер Продактс Инк. Композиция для защиты свиней от инфекции ррсс-вируса (варианты) и вакцина, содержащая указанную композицию (варианты)
CA2894069C (en) * 2005-06-24 2019-02-26 Regents Of The University Of Minnesota Prrs viruses, infectious clones, mutants thereof, and methods of use
CA2620667A1 (en) * 2005-08-30 2007-04-12 Board Of Regents Of The University Of Nebraska Methods and compositions for vaccination of animals with prrsv antigens with improved immunogenicity
US8202717B2 (en) 2007-01-12 2012-06-19 The Board Of Trustees Of The University Of Illinois Non-simian cells for growth of porcine reproductive and respiratory syndrome (PRRS) virus
US7666585B2 (en) 2007-06-15 2010-02-23 Protatek International, Inc. Construction of chimera PRRSV, compositions and vaccine preparations
ES2389748T3 (es) * 2007-06-25 2012-10-31 South Dakota State University Virus del síndrome reproductivo y respiratorio porcino de tipo 1 norteamericano recombinante y métodos de uso
KR101653177B1 (ko) * 2008-08-25 2016-09-01 베링거잉겔하임베트메디카인코퍼레이티드 고병원성 돼지 생식기 및 호흡기 증후군(ｈｐ ｐｒｒｓ)에 대한 백신
US8012735B2 (en) * 2009-03-02 2011-09-06 University Of Kentucky Research Foundation Infectious cDNA clone of the modified live virus vaccine strain of Equine arteritis virus
AR078253A1 (es) 2009-09-02 2011-10-26 Boehringer Ingelheim Vetmed Metodos para reducir la actividad antivirica en composiciones pcv-2 y composiciones pcv-2 con mejor inmunogenicidad
UA107940C2 (en) * 2009-09-10 2015-03-10 Merial Ltd The vaccine composition that includes the saponin-containing adjuvant
UA108902C2 (uk) * 2010-11-10 2015-06-25 Вірус північноамериканського репродуктивного та респіраторного синдрому свиней (prrs) та його застосування
SG192821A1 (en) 2011-02-17 2013-09-30 Boehringer Ingelheim Vetmed Commercial scale process for production of prrsv
ES2550258T3 (es) 2011-02-17 2015-11-05 Boehringer Ingelheim Vetmedica Gmbh Nueva cepa del PRRSV europea
EP2737059A1 (en) 2011-07-29 2014-06-04 Boehringer Ingelheim Vetmedica GmbH Novel prrs virus inducing type i interferon in susceptible cells
US9187731B2 (en) 2011-07-29 2015-11-17 Boehringer Ingelheim Vetmedica Gmbh PRRS virus inducing type I interferon in susceptible cells
UA114503C2 (uk) 2012-04-04 2017-06-26 Зоетіс Сервісіз Ллс Комбінована вакцина pcv та mycoplasma hyopneumoniae
US9120859B2 (en) 2012-04-04 2015-09-01 Zoetis Services Llc Mycoplasma hyopneumoniae vaccine
UA114504C2 (uk) 2012-04-04 2017-06-26 Зоетіс Сервісіз Ллс Комбінована вакцина pcv, mycoplasma hyopneumoniae та prrs
CA2872789C (en) 2012-05-17 2019-09-03 Zoetis Llc Effective vaccination against porcine reproductive and respiratory syndrome (prrs) virus prior to weaning
WO2014150822A2 (en) 2013-03-15 2014-09-25 Boehringer Ingelheim Vetmedica, Inc. Porcine reproductive and respiratory syndrome virus, compositions, vaccine and methods of use
EP3049106A1 (en) 2013-09-25 2016-08-03 Zoetis Services LLC Pcv2b divergent vaccine composition and methods of use
EA039060B1 (ru) * 2013-12-20 2021-11-29 Бёрингер Ингельхайм Ветмедика Гмбх Вариант вируса ppcc, способ его получения с помощью молекулы нуклеиновой кислоты, конструкции днк или клетки и его применение для лечения и профилактики ррсс
CN104198773A (zh) * 2014-08-29 2014-12-10 苏州市吴中区胥口广博模具加工厂 三轴联动式大型电路板测试夹具的第二转轴组
TWI554609B (zh) 2014-11-19 2016-10-21 國立屏東科技大學 抗豬生殖與呼吸綜合症病毒感染之重組融合抗原基因、重組融合抗原蛋白及含彼之次單位疫苗組成物
TWI799365B (zh) 2015-08-31 2023-04-21 德商百靈佳殷格翰維美迪加股份有限公司 用於先天性痙攣症之瘟疫病毒疫苗
EP3389706A1 (en) 2015-12-14 2018-10-24 Boehringer Ingelheim Vetmedica, Inc. Hybrid core feline vaccines
BR112019000887A2 (pt) 2016-08-05 2019-04-30 Hipra Scientific, S.L.U. clone de cdna do vírus da síndrome reprodutiva e respiratória porcina e usos do mesmo
CN110072547B (zh) 2016-12-14 2024-04-30 硕腾服务有限责任公司 断奶前对抗欧洲猪繁殖与呼吸综合征(prrs)病毒株的有效疫苗接种
CN107586780B (zh) * 2017-10-25 2019-10-11 中国农业科学院兰州兽医研究所 一种抑制猪繁殖与呼吸综合征病毒的长链非编码rna
CN109943590B (zh) * 2019-04-18 2022-11-18 西南大学 一种复制缺陷型猪圆环病毒、其制备方法及应用
CN111996174A (zh) * 2020-02-06 2020-11-27 广西大学 猪繁殖与呼吸综合征病毒及其克隆载体和插入基因方法
US20250332242A1 (en) 2024-04-30 2025-10-30 Zoetis Services Llc Porcine endogenous retrovirus (perv)-free porcine circovirus type 2d-based vaccines and methods of use
US20250332243A1 (en) 2024-04-30 2025-10-30 Zoetis Services Llc Methods of manufacturing porcine endogenous retrovirus (perv) free animal health vaccines

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3137631A (en) 1959-12-01 1964-06-16 Faberge Inc Encapsulation in natural products
US3959457A (en) 1970-06-05 1976-05-25 Temple University Microparticulate material and method of making such material
US4015100A (en) 1974-01-07 1977-03-29 Avco Everett Research Laboratory, Inc. Surface modification
JPS5186117A (en) 1975-01-27 1976-07-28 Tanabe Seiyaku Co Johoseibiryushiseizainoseiho
US4205060A (en) 1978-12-20 1980-05-27 Pennwalt Corporation Microcapsules containing medicament-polymer salt having a water-insoluble polymer sheath, their production and their use
US4452747A (en) 1982-03-22 1984-06-05 Klaus Gersonde Method of and arrangement for producing lipid vesicles
US4744933A (en) 1984-02-15 1988-05-17 Massachusetts Institute Of Technology Process for encapsulation and encapsulated active material system
US5008050A (en) 1984-06-20 1991-04-16 The Liposome Company, Inc. Extrusion technique for producing unilamellar vesicles
US4921706A (en) 1984-11-20 1990-05-01 Massachusetts Institute Of Technology Unilamellar lipid vesicles and method for their formation
US4606940A (en) 1984-12-21 1986-08-19 The Ohio State University Research Foundation Small particle formation and encapsulation
US5009956A (en) 1987-02-24 1991-04-23 Univ Minnesota Phospholipase A2-resistant liposomes
IT8819772A0 (it) * 1988-03-15 1988-03-15 Honeywell Bull Spa Dispositivo selettivo a terra per apparecchiature elettroniche.
US4927637A (en) 1989-01-17 1990-05-22 Liposome Technology, Inc. Liposome extrusion method
US4944948A (en) 1989-02-24 1990-07-31 Liposome Technology, Inc. EGF/Liposome gel composition and method
US5132117A (en) 1990-01-11 1992-07-21 Temple University Aqueous core microcapsules and method for their preparation
DE69201441T3 (de) 1991-06-06 2008-12-04 Boehringer Ingelheim Vetmedica Gmbh Erreger der mysteriösen schweinekrankheit,impfstoff-zusammensetzungen und diagnose kits.
US6042830A (en) 1992-08-05 2000-03-28 Boehringer Ingelheim Vetmedica, Inc. Viral agent associated with mystery swine disease
US5846805A (en) 1991-08-26 1998-12-08 Boehringer Ingelheim Animal Health, Inc. Culture of swine infertility and respiratory syndrome virus in simian cells
CA2076744C (en) 1991-08-26 2000-06-27 Danny W. Chladek Viral agent associated with mystery swine disease
DE601062T1 (de) 1991-08-26 1995-05-18 David Allen Benfield Vakzine gegen und diagnosemethode für das schweine-unfruchtbarkeits- und atmungs-syndrom (suas).
WO1993006211A1 (en) 1991-09-16 1993-04-01 Collins James E Vaccine for mystery swine disease and method for diagnosis thereof
FR2686097B1 (fr) 1992-01-14 1994-12-30 Rhone Merieux Preparation d'antigenes et de vaccins de virus de la mystery disease, antigenes et vaccins obtenus pour la prevention de cette maladie.
US5203054A (en) 1992-09-28 1993-04-20 Emhart Inc. Retainer for trunk lid torsion bars
US6251397B1 (en) * 1992-10-30 2001-06-26 Iowa State University Research Foundation, Inc. Proteins encoded by polynucleic acids isolated from a porcine reproductive and respiratory syndrome virus and immunogenic compositions containing the same
US6592873B1 (en) 1992-10-30 2003-07-15 Iowa State University Research Foundation, Inc. Polynucleic acids isolated from a porcine reproductive and respiratory syndrome virus (PRRSV) and proteins encoded by the polynucleic acids
US6773908B1 (en) * 1992-10-30 2004-08-10 Iowa State University Research Foundation, Inc. Proteins encoded by polynucleic acids of porcine reproductive and respiratory syndrome virus (PRRSV)
US5695766A (en) 1992-10-30 1997-12-09 Iowa State University Research Foundation Highly virulent porcine reproductive and respiratory syndrome viruses which produce lesions in pigs and vaccines that protect pigs against said syndrome
KR100374295B1 (ko) 1993-02-08 2003-12-24 바이엘 코포레이션 돼지생식및호흡증후군바이러스의생육방법과백신에서그의용도
ES2074950B1 (es) 1993-09-17 1996-03-16 Iberica Cyanamid Vacuna para la prevencion de la enfermedad reproductiva y respiratoria de la cerda.
DE69530227T2 (de) 1994-04-15 2004-04-01 Temple University Methode zum einkapseln mittels eines wässrigen lösungsmittels und mikrokapseln
PT783321E (pt) * 1994-08-05 2006-08-31 Univ Minnesota Sequencia nucleotidica viral vr-2332 e metodos de utilizacao
DE69632658T2 (de) 1995-03-14 2005-06-09 Akzo Nobel N.V. Expression in der selben Zelle von Polypeptide vom schweinen reproduktiven und respiratorischen Syndrom
EE04741B1 (et) 1996-03-01 2006-12-15 Schering Corporation Sigade sigimis- ja hingamissündroomi vaktsiin
EP0839912A1 (en) 1996-10-30 1998-05-06 Instituut Voor Dierhouderij En Diergezondheid (Id-Dlo) Infectious clones of RNA viruses and vaccines and diagnostic assays derived thereof
AU7960598A (en) 1997-06-05 1998-12-21 Origen, Inc. Recombinant porcine reproductive and respiratory syndrome virus (prrsv) for use as a vaccine
US6288199B1 (en) * 1999-11-02 2001-09-11 Ppg Industries Ohio, Inc. Blocked isocyanate-based compounds and compositions containing the same

Also Published As

Publication number Publication date
BRPI9905902B1 (pt) 2015-09-01
JP2008289485A (ja) 2008-12-04
US7232680B2 (en) 2007-06-19
BR9905902A (pt) 2000-12-12
CA2290220A1 (en) 2000-06-22
JP4113642B2 (ja) 2008-07-09
DE69928209D1 (de) 2005-12-15
CN1171996C (zh) 2004-10-20
PT1627919E (pt) 2014-05-02
DE69928209T2 (de) 2006-06-08
CY1105680T1 (el) 2014-07-02
US20020172690A1 (en) 2002-11-21
JP4335287B2 (ja) 2009-09-30
NZ513289A (en) 2003-04-29
EP1018557B1 (en) 2005-11-09
CY1115010T1 (el) 2016-12-14
DE69928209T9 (de) 2006-10-19
EP1018557B9 (en) 2006-06-28
DK1018557T3 (da) 2005-12-05
CA2440933A1 (en) 2000-06-22
BRPI9905902B8 (pt) 2021-05-25
JP2008131957A (ja) 2008-06-12
ATE309364T1 (de) 2005-11-15
AR025146A1 (es) 2002-11-13
DK1018557T5 (da) 2006-05-15
ES2251162T3 (es) 2006-04-16
MXPA03009354A (es) 2004-03-02
HK1029140A1 (en) 2001-03-23
ES2459568T3 (es) 2014-05-09
JP2008113670A (ja) 2008-05-22
ZA997289B (en) 2001-05-24
EP1627919B1 (en) 2014-02-12
CN1263945A (zh) 2000-08-23
JP2001218591A (ja) 2001-08-14
JP4159242B2 (ja) 2008-10-01
US6500662B1 (en) 2002-12-31
NZ501264A (en) 2001-09-28
EP1018557A2 (en) 2000-07-12
EP1018557A3 (en) 2002-05-02
JP2000189178A (ja) 2000-07-11
JP4130729B2 (ja) 2008-08-06
JP2004081218A (ja) 2004-03-18
JP2001224384A (ja) 2001-08-21
AU6173399A (en) 2000-06-29
EP1627919A1 (en) 2006-02-22
AU769841B2 (en) 2004-02-05
CA2290220C (en) 2013-11-19
DK1627919T3 (en) 2014-03-10

Similar Documents

Publication Publication Date Title
AR058249A2 (es) Una molecula aislada de polinucleotido que comprende una secuencia de adn que codifica una molecula infecciosa de arn que codifica un virus prrs norteamericano, celula transfectada y vacuna
CA2272046A1 (en) Infectious clones of rna viruses and vaccines and diagnostic assays derived thereof
Fernández et al. The motif V of plum pox potyvirus CI RNA helicase is involved in NTP hydrolysis and is essential for virus RNA replication
AR044724A1 (es) Promotores del virus de la rizadura amarilla del cestrum
CA2389206A1 (en) Activation of hcv-specific t cells
MX9204685A (es) Secuencia de adn que codifica una proteina superficial externa (ospa) o derivado de la misma composicion de vacuna qe comprende tal proteina.
JPS63196293A (ja) 融合蛋白
BR0010361A (pt) Seq ências genÈmicas de neisseria e uso destas
TR200401186T4 (tr) Rekombinant bir RNA-virüs oluşumunu yönlendirebilen nükleik asit sekansları içerikli suni kromozom yapıları.
DE60038620D1 (de) Dna immunisierung gegen chlamydia infektion
WO2000061737A3 (en) Production of attenuated negative stranded RNA virus vaccines
HUP0500722A2 (hu) Attenuált veszettség vírus, a veszettség elleni vakcináláshoz és a központi idegrendszer génterápiájához egy nukleoprotein mutációval a foszforilezés helyén
PT1119630E (pt) Construcoes de acido nucleico para imunizacao genetica
Beer et al. Phylogenetic Analysis of the 5′‐Untranslated Region of German BVDV Type II Isolates
DK1151079T3 (da) 1-deoxy-D-xylulose-5-phosphatreduktoisomerase og anvendelsesfremgangsmåder
DE69929530D1 (de) Attenuierte pferdeherpesvirus
DE60040219D1 (de) Infektiöses cdna klon des gb-virus b und dessen verwendungen
DE69922212D1 (de) Impfstoff enthaltend zytokin-induzierte heat shock proteine (hsp)
ATE115964T1 (de) Non-a non-b sequenzen.
ATE160377T1 (de) Erzeugung von hybrid-genen und proteinen durch rekombination mittels viren
IL149415A0 (en) Adjuvanted genetic vaccines
DE60229966D1 (de) Diabetesmodell
ES2367245T8 (es) Virus recombinante que expresa adn foráneo que codifica cd80 felino, cd28 felino, ctla-4felino o cd86 felino y usos del mismo.
ATE389726T1 (de) Infektiöse vektoren und pflanzenklone, die sich von turnip mosaikvirus herleiten
TH62970A (th) วัคซีนไวรัสโรคเบอร์ซาอักเสบติดต่อชนิดบรอดสเปคตรัม (broad spectrum)

Legal Events

Date Code Title Description
FC Refusal